Tags : ixekizumab

Eli Lilly to Present Data of Taltz (ixekizumab) for Patients

Shots: Eli Lilly shared new results from a subgroup analysis of the P-IIIb/IV, 52-wks. SPIRIT-H2H study assessing Taltz vs Humira (adalimumab) in biologic-naïve patients with active PsA with 1EPs as ACR50 & PASI 100 @24wks. The study compares Taltz and Humira in subgroups of patients on monothx./ concomitant MTX/ concomitant MTX along with csDMARD including […]Read More

Eli Lilly’s Taltz (ixekizumab) Receives the US FDA’s Approval for

Shots: The approval is based on P-III study assessing Taltz (20mg for <25kg/40mg for 25-50kg/80 mg for >50 kg @12wks., with 40/80/160mg starting doses, respectively) vs PBO in 171 patients aged 6-18 yrs. with mod. to sev. PsO who are candidates for systemic therapy or phototherapy The P-III study results: patients achieving PASI 75 (89% […]Read More

Eli Lilly’s Taltz (ixekizumab) Receives Third US FDA’s Approval for

Shots: The approval is based on two P-III studies assessing Taltz vs PBO in 657 patients with active AS, randomized into two groups i.e, COAST-V in patients who are bDMARD-naïve and COAST-W in patients who are intolerant or have an inadequate response to TNF inhibitors The two P-III study results: patients achieved ASAS40 @16wks. COAST-V […]Read More

Eli Lilly to Report Positive Results of Taltz (ixekizumab) in

Shots: The P-IIIb/IV SPIRIT-H2H study results involve assessing of Taltz vs Humira (adalimumab) in 566 patients with PsA who are biologic DMARD-naive for 52wks. The P-IIIb/IV SPIRIT-H2H study results: met its 1EPs & 2Eps i.e, @24wks. reduction by 50% in disease activity as defined by ACR50; PASI100 (36% vs 28%) & superior to Humira, ACR50 […]Read More

Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years

Shots: The P-III study results involves assessing of Taltz in patients with moderate to severe plaque psoriasis for 5yrs.in addition to an extension study UNCOVER-1 Collective results: 90%+ maintained skin clearance as measured by PASI 75; @264wks. PASI 75 (94.3); PASI 90 (81.8%); PASI 100 (46.6%), presented at WCD with additional data of UNCOVER-3 study […]Read More

Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study

Shots: The P-III COAST-X study involves assessing of Taltz (ixekizumab) vs PBO in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who are biologic disease-modifying anti-rheumatic drug (bDMARD) naive for 52wks. The P-III COAST-X study results:  @16 & 52wks. met its 1Eps & 2Eps; improvement in the signs and symptoms of nr-axSpA; improvement in ASDAS & BASDAI; […]Read More